Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Branger

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Immunology|March 5, 2004
P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemiaBernt van den Blink, Judith Branger, Sebastiaan Weijer, et al.
Shock (Augusta, Ga.)|November 17, 2004
Platelet-activating factor receptor-deficient mice show an unaltered clearance of nontypeable Haemophilus influenzae from their respiratory tractJudith Branger, Catharina W Wieland, Sandrine Florquin, et al.
Blood|February 11, 2003
Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemiaJudith Branger, Bernt van den Blink, Sebastiaan Weijer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2002
Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemiaJudith Branger, Bernt van den Blink, Sebastiaan Weijer, et al.
The Lancet Regional Health. Europe|October 17, 2022
Improving indicator-condition guided testing for HIV in the hospital setting (PROTEST 2·0): A multicenter, interrupted time-series analysisSaskia J Bogers, Maarten F Schim van der Loeff, Anders Boyd, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2021
Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter TrialThijs Ten Doesschate, Sander Kuiper, Cees van Nieuwkoop, et al.
The Journal of Infectious Diseases|November 19, 2022
Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary VaccinationMarlou J Jongkees, Daryl Geers, Kathryn S Hensley, et al.
Plos Medicine|October 27, 2022
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyKathryn S Hensley, Marlou J Jongkees, Daryl Geers, et al.
Plos Medicine|January 7, 2023
Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyKathryn S Hensley, Marlou J Jongkees, Daryl Geers, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Immunology|March 5, 2004
P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemiaBernt van den Blink, Judith Branger, Sebastiaan Weijer, et al.
Shock (Augusta, Ga.)|November 17, 2004
Platelet-activating factor receptor-deficient mice show an unaltered clearance of nontypeable Haemophilus influenzae from their respiratory tractJudith Branger, Catharina W Wieland, Sandrine Florquin, et al.
Blood|February 11, 2003
Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemiaJudith Branger, Bernt van den Blink, Sebastiaan Weijer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2002
Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemiaJudith Branger, Bernt van den Blink, Sebastiaan Weijer, et al.
The Lancet Regional Health. Europe|October 17, 2022
Improving indicator-condition guided testing for HIV in the hospital setting (PROTEST 2·0): A multicenter, interrupted time-series analysisSaskia J Bogers, Maarten F Schim van der Loeff, Anders Boyd, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2021
Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter TrialThijs Ten Doesschate, Sander Kuiper, Cees van Nieuwkoop, et al.
The Journal of Infectious Diseases|November 19, 2022
Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary VaccinationMarlou J Jongkees, Daryl Geers, Kathryn S Hensley, et al.
Plos Medicine|October 27, 2022
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyKathryn S Hensley, Marlou J Jongkees, Daryl Geers, et al.
Plos Medicine|January 7, 2023
Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyKathryn S Hensley, Marlou J Jongkees, Daryl Geers, et al.
Pageof 2